08 July 2026
08 July 2026
Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.
The biotech’s potential launch on the public markets would help fuel development of its clinical-stage, melanocortin-focused pipeline.
Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery.
Vivani’s NanoPortal technology delivers medication steadily over long periods of time.
The collaboration leverages Biocytogen’s antibody capabilities and Whitehawk’s ADC expertise to identify BsADCs.
The status was granted by the FDA's Office of Orphan Products Development and Office of Pediatric Therapeutics.
The acquisition is expected to close in the third quarter of 2026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
